Case Series of Individuals Treated with Naltrexone during Pregnancy for Opioid and/or Alcohol Use Disorder.
Journal
Journal of addiction medicine
ISSN: 1935-3227
Titre abrégé: J Addict Med
Pays: Netherlands
ID NLM: 101306759
Informations de publication
Date de publication:
14 Feb 2024
14 Feb 2024
Historique:
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
aheadofprint
Résumé
There is a lack of knowledge about the relative safety and efficacy of naltrexone for the treatment of pregnant individuals with opioid and/or alcohol use disorder, including the range of outcomes, in both the pregnant individual and the infant, over the course of peripartum period. Our objective was to describe these outcomes in a cohort of pregnant individuals on naltrexone. In this prospective case series, 7 pregnant individuals with opioid use disorder (OUD) or alcohol use disorder (AUD) treated with naltrexone were followed from pregnancy through 12 months after delivery. Clinical treatment protocols and outcomes related to safety and efficacy during pregnancy, delivery, and the postpartum period are described. There were 4 pregnant individuals with OUD and 3 with AUD, of which 3 were managed with oral and 4 with extended-release naltrexone. The mean gestational age at study enrollment was 21.7 (SD, 12) weeks. Of the 7 participants, there was no return to nonprescribed opioid use and 2 who experienced a return to alcohol use over the course of the study. All individuals delivered vaginally at a mean of 37 weeks gestation without any peripartum pain difficulties. Five of the individuals (71.4%) remained on naltrexone 12 months after delivery. There were no reported fetal anomalies and one preterm delivery. None of the infants developed neonatal opioid withdrawal syndrome. For pregnant individuals with OUD or AUD treated with naltrexone, there were low rates of return to nonprescribed use and reassuring pregnant person and infant outcomes to 12 months postpartum.
Identifiants
pubmed: 38354121
doi: 10.1097/ADM.0000000000001293
pii: 01271255-990000000-00287
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 American Society of Addiction Medicine.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest.
Références
Saia KA, Schiff D, Wachman EM, et al. Caring for pregnant women with opioid use disorder in the USA: Expanding and improving treatment. Curr Obstet Gynecol Rep. 2016;5:257–263.
Haight SC, Ko JY, Tong VT, et al. Opioid use disorder documented at delivery hospitalization—United States, 1999–2014. MMWR Morb Mortal Wkly Rep. 2018;67(31):845–849.
Denny CH, Acero CS, Terplan M, et al. Trends in alcohol use among pregnant women in the U.S., 2011–2018. Am J Prev Med. 2020;59(5):768–769.
Murphy CE 4th, Wang RC, Montoy JC, et al. Effect of extended-release naltrexone on alcohol consumption: A systematic review and meta-analysis. Addiction. 2022;117(2):271–281 Published online May 25, 2021.
Minozzi S, Amato L, Bellisario C, et al. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev. 2013;12:CD006318.
Nunes EV, Krupitsky E, Ling W, et al. Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): Who will respond? J Addict Med. 2015;9(3):238–243.
Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377(9776):1506–1513.
Vivitrol. http://www.vivitrol.com. Accessed October 15, 2023.
Jones HE, Chisolm MS, Jansson LM, et al. Naltrexone in the treatment of opioid-dependent pregnant women: The case for a considered and measured approach to research. Addiction. 2013;108(2):233–247.
Wachman EM, Saia K, Miller M, et al. Naltrexone treatment for pregnant women with opioid use disorder compared with matched buprenorphine control subjects. Clin Ther. 2019;41(9):1681–1689.
Towers CV, Katz E, Weitz B, et al. Use of naltrexone in treating opioid use disorder in pregnancy. Am J Obstet Gynecol. 2020;222(1):83.e1–e83.e8.
Hulse GK, O’Neill G, Pereira C, et al. Obstetric and neonatal outcomes associated with maternal naltrexone exposure. Aust N Z J Obstet Gynaecol. 2001;41(4):424–428.
Kelty E, Hulse G. A retrospective cohort study of the health of children prenatally exposed to methadone, buprenorphine or naltrexone compared with non-exposed control children. Am J Addict. 2017;26(8):845–851.
Lexi-drugs online. http://online.lexi.com. Accessed on October 15, 2023.
Kelty E, Hulse G. A retrospective cohort study of birth outcomes in neonates exposed to naltrexone in utero: A comparison with methadone-, buprenorphine- and non-opioid-exposed neonates. Drugs. 2017;77(11):1211–1219.
Deflorimonte C, Glissendorf V, Hofer J, et al. National Provider Survey: Use of naltrexone for pregnant individuals with substance use disorders. J Addict Med. 2023;17(6):736–738 Published online September 20, 2023.